Goodfellow Gems are chosen by Goodfellow Director, Bruce Arroll to be either practice changing or thought provoking. You are being mailed these as you are a member of the Goodfellow learning community.

Continue ACE inhibitors and ARBs amid COVID-19 outbreak

Patients should not stop taking their angiotensin-converting-enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), despite theoretical concerns that their use might worsen outcomes in the event of infection with COVID-19, according to a new statement from the American Heart Association, the American College of Cardiology, the Heart Failure Society of America and the European Society of Hypertension.¹

An article published in Lancet Resp Medicine 11 March 2020 suggested that coronavirus can bind to target cells through ACE-2 receptors, and speculates that ACE-2 upregulation from ACEI and ARB could increase the risk of developing severe and fatal COVID-19. There is no clinical data to support that contention.

At this point the risk to a patients health from cardiovascular causes and events of stopping these medications would outweigh any theoretical harm from COVID -19.

This Gem has the support of Associate Professors Rinki Murphy and Gerry Devlin and Dr Hari Talreja.

Reference:

 Heart Groups: Patients with COVID-19 Should Continue ACE Inhibitors & ARBs NEJM (2020) View here

Click here to view more Gems



Join MercyAscot and the Goodfellow Unit for a day of self-isolation and free CPD webinars.

28th March



If this email was forwarded to you and you would like to automatically receive Goodfellow Gems Click here.

Copyright © 2020 Goodfellow Unit, All rights reserved.

Our mailing address is:

Goodfellow Unit University of Auckland, Grafton Campus, Bldg 507 22-30 Park Ave, Grafton, Auckland, Auckland 1023 New Zealand